Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 9/20 | 0.31 |
| ▸ | CA2 | P00918 | 9/20 | 0.31 |
| ▸ | CA9 | Q16790 | 8/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA3 | P07451 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA6 | P23280 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA7 | P43166 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL795481 | 0.86 | USP2 (0.50) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL5376935 | 0.82 | ALDH1A1 (0.64) | USP2TSHRKDM4EALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL2285973 | 0.80 | TSHR (0.61) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL5792262 | 0.76 | ALDH1A1 (0.68) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL576408 | 0.75 | TSHR (0.88) | USP2TSHRKDM4EALDH1A1LMNA | |
| Busulfan SCHEMBL4373 | 0.75 | TSHR (1.00) | USP2TSHRKDM4EALDH1A1LMNA | |
| Busulfan SCHEMBL4764696 | 0.75 | TSHR (1.00) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL27006824 | 0.75 | ALDH1A1 (0.54) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL18174906 | 0.75 | TSHR (0.54) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL14891731 | 0.75 | MEN1 (0.38) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392298-B1 | FUSED HETEROCYCLIC COMPOUNDS | AMGEN INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070135425-A1 | Fused heterocyclic compounds | AMGEN INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-7125885-B2 | Fused heterocyclic compounds | AMGEN INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050148617-A1 | Fused heterocyclic compounds | TULARIK INC. | 2005-07-07 | — | — | US | disclosed |
| EP-1392298-A4 | FUSED HETEROCYCLIC COMPOUNDS | TULARIK INC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6858619-B2 | Fused heterocyclic compounds | AMGEN INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-6809104-B2 | COMPRISES 6H-PYRIDO(4,3-B)CARBAZOLE-CONTAINING COMPOUNDS FOR TREATMENT OF OBESITY, EATING/ANXIETY/MOOD DISORDERS AND OTHER DISEASES MEDIATED BY G-PROTEIN-COUPLED-RECEPTORS AND MELANIN-CONCENTRATING HORMONE RECEPTORS | TULARIK INC. | 2004-10-26 | — | — | US | disclosed |
| EP-1392298-A2 | FUSED HETEROCYCLIC COMPOUNDS | Tularik Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030176694-A1 | Fused heterocyclic compounds | AMGEN INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030023085-A1 | Fused heterocyclic compounds | TULARIK INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2002089729-A2 | FUSED HETEROCYCLIC COMPOUNDS | TULARIK INC. (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023085-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | USP2 3831/4885TSHR 433/4885KDM4E 3194/4885 |
| US-20050148617-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | USP2 3831/4885TSHR 433/4885KDM4E 3194/4885 |
| US-20030176694-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | USP2 3831/4885TSHR 433/4885KDM4E 3194/4885 |
| US-20070135425-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | USP2 3831/4885TSHR 433/4885KDM4E 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.